| Original language | English |
|---|---|
| Pages (from-to) | e485-e487 |
| Journal | Clinical Genitourinary Cancer |
| Volume | 17 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Jun 2019 |
Keywords
- Chemotherapy
- High dose chemotherapy
- Non-seminomatous germ cell tumor
- Orchiectomy
- Testicular cancer
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical Genitourinary Cancer, Vol. 17, No. 3, 01.06.2019, p. e485-e487.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment
AU - Vicier, Cécile
AU - Baciarello, Giulia
AU - Arfi-Rouche, Julia
AU - Massard, Christophe
AU - Loriot, Yohann
AU - Albiges, Laurence
AU - Cojean-Zelek, Isabelle
AU - Fizazi, Karim
N1 - Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , and Sanofi ; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis , Incyte , and Pfizer , outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest. Funding Information: Christophe Massard reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Novartis, Pfizer, Roche, Sanofi, and Orion; Principal/sub-Investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo Pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor; research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi; and nonfinancial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Yohann Loriot reports grants, personal fees, and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Astra Zenica, BMS, Roche, and Seattle Genetics; grants and personal fees from Sanofi; personal fees from Clovis, Incyte, and Pfizer, outside the submitted work. In addition, Yohann Loriot has a patent in the United States: 62/455211 and a patent pending in Europe: 17209098.7. Laurence Albiges reports honoraria/consulting for Pfizer, BMS, Ipsen, Peloton Therapeutics, Roche, MSD, and Novartis. Karim Fizazi reports participation in advisory boards/honorarium for Amgen, Astellas, Astra Zeneca, Bayer, Clovis, Curevac, Essa, Genentech, Janssen, MSD, Orion, and Sanofi. The remaining authors have stated that they have no conflicts of interest.
PY - 2019/6/1
Y1 - 2019/6/1
KW - Chemotherapy
KW - High dose chemotherapy
KW - Non-seminomatous germ cell tumor
KW - Orchiectomy
KW - Testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=85061631968&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2019.01.010
DO - 10.1016/j.clgc.2019.01.010
M3 - Article
C2 - 30792009
AN - SCOPUS:85061631968
SN - 1558-7673
VL - 17
SP - e485-e487
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -